Plaque Psoriasis

Dermavant Sciences has submitted a supplemental new drug application to the FDA for its Vtama cream 1% for the topical treatment of atopic dermatitis in patients aged 2 years and older, according to a company press release.

In this video, Matthew Lewis, MD, MPH, clinical associate professor, of dermatology at Standford University, discusses racial and gender disparities that exist in psoriasis care.

In this video, Matthew Lewis, MD, MPH, clinical associate professor, of dermatology at Standford University, discusses risk factors for psoriasis.

In this video, Matthew Lewis, MD, MPH, clinical associate professor, of dermatology at Standford University, discusses treatments in the pipeline for psoriasis.

In this video, Matthew Lewis, MD, MPH, clinical associate professor, of dermatology at Standford University, discusses the unmet needs of patients with psoriasis.

In this video, Matthew Lewis, MD, MPH, clinical associate professor, of dermatology at Standford University, discusses the latest treatment advancements for psoriasis.

Patients with atopic dermatitis and plaque psoriasis who were treated with a topical phosphodiesterase 4 inhibitor exhibited significant improvement, according to a study.

Vtama cream 1% may be used in combination with an injectable biologic for the treatment of plaque psoriasis, according to a Schweiger Dermatology Group press release.